[av_one_full first min_height=” vertical_alignment=” space=” custom_margin=” margin=’0px’ padding=’0px’ border=” border_color=” radius=’0px’ background_color=” src=” background_position=’top left’ background_repeat=’no-repeat’ animation=”]
[av_heading heading=’‘Dengvaxia girl’ hospitalized; DOH-6 wary of test results’ tag=’h3′ style=’blockquote modern-quote’ size=” subheading_active=’subheading_below’ subheading_size=’15’ padding=’10’ color=” custom_font=” av-medium-font-size-title=” av-small-font-size-title=” av-mini-font-size-title=” av-medium-font-size=” av-small-font-size=” av-mini-font-size=” admin_preview_bg=”][/av_heading]
[av_textblock size=” font_color=” color=” av-medium-font-size=” av-small-font-size=” av-mini-font-size=” admin_preview_bg=”]
January 28, 2018
[/av_textblock]
[av_textblock size=” font_color=” color=” av-medium-font-size=” av-small-font-size=” av-mini-font-size=” admin_preview_bg=”]
ILOILO City – The Department of Health (DOH) Region 6 is waiting for the laboratory test results of an 11-year-old girl recently admitted at the Western Visayas Medical Center (WVMC) in Mandurriao district.
According to DOH, the girl received three doses of anti-dengue vaccine Dengvaxia when she was still enrolled at a public school in Manila – on April 11 and Nov. 15, 2016, and May 5, 2017.
The girl had fever when she was hospitalized on Jan. 16.
Dengvaxia manufacturer Sanofi Pasteur announced late last year that the vaccine works as expected in people already exposed to the dengue virus but in those who haven’t, the vaccination may result to an elevated risk of severe disease developing from a subsequent dengue infection.
The girl was discharged on Wednesday although the results of her laboratory tests sent to the Research Institute for Tropical Medicine in Metro Manila were yet to be released, said Dr. Reynilyn Reyes, head of DOH Region 6’s family, health and nutrition cluster.
The girl had dengue infection in 2011, it was learned.
According to the mother, she signed a consent card before her child was vaccinated in 2016 and 2017.
In June last year her daughter had fever and joint pains, she said, and recalled similar bouts in July and December.
Prior to the girl’s Jan. 16 hospitalization, she was brought to a rural health center.
Reyes said the child had already recovered when she was discharged on Wednesday.
Dengvaxia, approved for use in individuals from nine to 45 years of age, is the first vaccine in the world licensed for the prevention of dengue.
Former Health secretary Janette Garin has once again emphasized that she is ready to face any liabilities in case the Dengvaxia vaccines can be proven to cause negative side effects to individuals without prior dengue infection.
“For my part, I affirm that this was the decision of the whole institution. We did it based on the available data at that time, and on the fact that the number of dengue infections was increasing, and that there was no cure,” said Garin. (PNA)
[/av_textblock]
[/av_one_full]
